AI-Developed Drug Rentosertib Reverses Biological Age in Rare Lung Disease Trial

Rentosertib, an AI-designed drug, reduced biological age by 3-4 years in patients with a rare lung disease, per a Nature Biotechnology study. The finding is preliminary and based on a small trial, but it marks a first for AI-discovered therapeutics targeting aging. If replicated, it could shift drug development and longevity research.